Plymouth Meeting, PA – August 10, 2015: CRF Health, the leading global provider of electronic Clinical Outcome Assessment (eCOA) solutions for the life sciences industry, introduces a complete TrialMax® eCOA solution specifically for oncology clinical trials. Developed based on CRF Health's experience of delivering over 100 successful global oncology studies, the solution streamlines data collection by combining an eCOA capture system with intuitive site and patient management tools. Reporting concomitant medication data is also simplified, enabling sponsors to collect complete data while reducing patient and investigator burden.
The length, complexity and increased data demands of oncology trials places a considerable burden on patients, sites and study teams alike. The identification of concomitant medication also brings its own challenges. CRF Health has incorporated its new TrialMax ConMed™ solution into the platform, allowing patients to easily report concomitant medication taken during a trial in real-time and deliver this data to investigators. This not only helps sponsors in identifying which side effects are related to the study drug, but minimizes risk for resulting regulatory submissions.
"Busy site visits and sick patients taking multiple medications means that both investigators and patients may find it difficult to keep track of their condition in a way that meets the requirements of a trial's protocol. We have created this solution to support sponsors with the common problems they face in oncology trials and to collect data which shows the efficacy of the drug in near to real-time”, comments Rauha Tulkki-Wilke, VP Product and Service Management at CRF Health. “In doing so, we have been able to reduce burden on patients and site staff, resulting in improved retention and adherence, two of the biggest challenges in oncology studies.”
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.